GoodRx Holdings, Inc. (GDRX) Misses Q4 EPS by 1c; Guides Q1 Revs Below the Street
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
GoodRx Holdings Inc. (GDRX) PT Lowered to $30 at Goldman Sachs
March 1, 2022 6:58 AM ESTGoldman Sachs analyst Eric Sheridan lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $30.00 (from $43.00) while maintaining a Buy rating following results.
The analyst commented, "We reiterate our Buy rating but lower our PT from $43 to $30 to reflect both lowered operating... More
GoodRx Holdings Inc. (GDRX) PT Lowered to $20 at JPMorgan
March 1, 2022 4:58 AM ESTJPMorgan analyst Doug Anmuth lowered the price target on GoodRx Holdings Inc. (NASDAQ: GDRX) to $20.00 (from $33.00) while maintaining a Underweight rating.
The analyst comments "GoodRx is focused on building the top consumer-focused digital healthcare platform in the US. Its core offering tracks... More
GoodRx (GDRX) Shares Down 28% on Q4 Miss, Weak Outlook
February 28, 2022 5:31 PM ESTGoodRx Holdings, Inc. (NASDAQ: GDRX) shares were trading around 28% lower after-hours following the companys disappointing Q4 results. Quarterly EPS came in at $0.09, missing the consensus estimate of $0.10.
Revenue was $213.3 million, compared to the consensus estimate of $217.53 million. Prescription Transactions revenue increased 21% year-over-year... More
